Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR

Rhea-AI Summary

Medtronic (NYSE: MDT) announced a strategic investment in Pi-Cardia, securing an option to strengthen its structural heart portfolio focused on complex transcatheter aortic valve replacement (TAVR). Medtronic will invest up to $80 million in Pi-Cardia and is expected to become the exclusive global commercial distributor of Pi-Cardia’s FDA-cleared ShortCut leaflet modification device in 2027.

The agreement also grants Medtronic an option to acquire Pi-Cardia after predefined milestones for an estimated upfront price of up to $210 million, plus potential earn-out payments. ShortCut demonstrated 100% successful leaflet splitting in pivotal trial patients with a favorable safety profile. Transactions remain subject to regulatory approval and customary closing conditions.

Positive

• Up to $80 million strategic investment into Pi-Cardia to support TAVR innovation
• Expected exclusive global distribution rights for ShortCut device starting in 2027
• Acquisition option with estimated upfront price of up to $210 million plus potential earn-outs
• Access to first FDA-cleared leaflet modification technology with successful pivotal trial outcomes
• Potential expansion of structural heart portfolio across US, Europe, Japan and other markets

Negative

• Total cash commitment could reach $80 million before any acquisition payments
• Acquisition option and distribution plans are subject to regulatory approval and closing conditions

Market Reaction – MDT

+6.16% $96.23 34.4x vol

15m delay

+6.16% Vs previous close

$96.23 Last Price

$91.26 $96.50 Day Range

$123.18B Market Cap

34.4x Rel. Volume

Following this news, MDT has gained 6.16%, reflecting a notable positive market reaction. Our momentum scanner has triggered 23 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $96.23. Trading volume is exceptionally heavy at 34.4x the average, suggesting very strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

Recent insider activity for MDT was classified as Net Selling, with 0 shares bought and 7,291 sold. ...

Analysis

Recent insider activity for MDT was classified as Net Selling, with 0 shares bought and 7,291 sold. Against that backdrop, regulatory approval and milestone conditions are key items to watch for this investment.

Key Figures

Strategic investment: up to $80 million Commercial distribution: 2027 Upfront acquisition price: up to $210 million

3 metrics

Strategic investment up to $80 million Investment into Pi-Cardia

Commercial distribution 2027 Expected exclusive global distribution of ShortCut

Upfront acquisition price up to $210 million Option to acquire Pi-Cardia upon predefined milestones

Historical Context

5 past events · Latest: Aug 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 20	Dividend announcement	Positive	+1.1%	Board approved a $0.72 quarterly cash dividend payable in October.
Aug 10	Partner clinical update	Positive	+1.4%	Medtronic provided $35 million in strategic capital to Orchestra BioMed.
Aug 06	Regulatory expansion	Positive	-0.1%	Affera received expanded CE Mark indication and FDA Breakthrough Device Designation.
Jul 20	Earnings scheduling	Neutral	+0.1%	Medtronic scheduled fiscal first-quarter results for September 1, 2026.
Jul 16	Acquisition completion	Positive	+3.8%	Medtronic completed its $650 million cash acquisition of SPR Therapeutics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive or neutral announcements in the supplied history generally aligned with positive 24-hour reactions, with one near-flat divergence.

Key Terms

tavr, fda-cleared, valve-in-valve tavr, leaflet modification, +1 more

5 terms

tavr medical

"complex transcatheter aortic valve replacement (TAVR) patients"

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that replaces a failing aortic heart valve by delivering a new valve through a blood vessel instead of opening the chest. It matters to investors because TAVR expands who can be treated, shortens hospital stays and recovery, and shapes revenue, regulatory risk and reimbursement for medical device makers, hospitals and insurers—similar to how a popular new product can reshape an industry’s market and costs.

fda-cleared regulatory

"the first FDA-cleared leaflet modification technology"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

valve-in-valve tavr medical

"enable valve-in-valve TAVR procedures"

Valve-in-valve TAVR is a minimally invasive heart procedure that places a new transcatheter valve inside a previously implanted surgical or transcatheter valve that has become worn or leaky. It matters to investors because it represents a market for repeat valve devices and related hospital services, influencing demand, device lifecycles, and reimbursement patterns for companies and health systems; think of it as installing a replacement cartridge inside an existing housing rather than replacing the whole machine.

leaflet modification medical

"successful leaflet splitting in all pivotal trial patients"

A leaflet modification is an officially approved change to the written information that accompanies a medicine or medical product—such as the patient information leaflet or the prescribing information—covering topics like dosage, side effects, warnings or instructions. Think of it as an updated instruction manual or warning label that must be authorized by regulators; it matters to investors because such changes can affect a product’s marketability, legal compliance, perceived safety and prescribing behavior.

earn-out payments financial

"plus additional potential earn-out payments post-acquisition"

Earn-out payments are extra sums promised to the seller of a business that are paid later only if the company meets agreed performance targets, such as revenue or profit levels. They matter to investors because they shift some acquisition risk from the buyer to the seller, affect future cash flow and reported purchase price, and can change how much value is ultimately paid for an acquisition—think of it like a performance bonus tied to how well the bought business performs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in Pi-Cardia Ltd. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation. 

Pi-Cardia's ShortCut™ device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut™ demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile.  

"As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance." 

Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions.  

"Our mission has been to make leaflet modification a standard part of complex TAVR," said Erez Golan, Chief Executive Officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification." 

The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth. 

Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies. 

About Pi-Cardia 

Pi-Cardia Ltd. is a privately held medical device company dedicated to developing innovative structural heart technologies that address unmet clinical needs. Its proprietary leaflet modification platform is designed to improve procedural outcomes and expand treatment options for patients undergoing transcatheter valve interventions. 

About Medtronic 

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission, to alleviate pain, restore health, and extend life, unites a global team of employees dedicated to transforming healthcare and improving lives around the world.  

Contacts:  

Kimberly Powell  
Public Relations 
+1-202-498-2601 

Ingrid Goldberg  
Investor Relations  
+1-763-505-2696 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-strategic-investment-in-pi-cardia-to-accelerate-innovation-for-complex-tavr-302865441.html

SOURCE Medtronic plc

FAQ

What did Medtronic (MDT) announce about its investment in Pi-Cardia on September 1, 2026?

Medtronic announced a strategic investment of up to $80 million in Pi-Cardia. According to Medtronic, the deal includes distribution rights for the ShortCut device and an acquisition option, aiming to strengthen its structural heart and complex TAVR portfolio.

How much is Medtronic (MDT) potentially paying to acquire Pi-Cardia?

Medtronic secured an option to acquire Pi-Cardia for an estimated upfront price of up to $210 million. According to Medtronic, this would be in addition to potential post-acquisition earn-out payments that could meaningfully increase the total consideration.

What is Pi-Cardia’s ShortCut device and why is it important for Medtronic (MDT) TAVR care?

ShortCut is the first FDA-cleared leaflet modification technology for valve-in-valve TAVR in patients at risk of coronary obstruction. According to Medtronic, it enables controlled leaflet splitting, helps preserve coronary access, and supports future transcatheter valve procedures in complex anatomy.

When will Medtronic (MDT) start exclusively distributing Pi-Cardia’s ShortCut device?

Medtronic is expected to become the exclusive global commercial distributor of ShortCut in 2027. According to Medtronic, its worldwide Structural Heart organization will expand physician access across the United States, Europe, Japan and other international markets, subject to regulatory approvals and conditions.

What clinical results has Pi-Cardia’s ShortCut device shown that matter to Medtronic (MDT) investors?

In FDA-reviewed pivotal studies, ShortCut achieved successful leaflet splitting in all treated patients with a favorable safety profile. According to Medtronic, this performance supports ShortCut as a reproducible leaflet modification tool for complex valve-in-valve TAVR cases and future structural heart procedures.

What strategic benefits does the Pi-Cardia investment bring to Medtronic’s (MDT) structural heart portfolio?

The investment gives Medtronic access to first-of-its-kind leaflet modification technology that addresses valve-in-valve TAVR challenges. According to Medtronic, it complements its leadership in transcatheter valve therapies and supports long-term growth by expanding treatment options for increasingly complex TAVR patients.